5 news items
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
YMAB
26 Apr 24
neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy
Y-mAbs to Present at 2024 ASCO Annual Meeting
YMAB
25 Apr 24
of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastomaPoster Number
Y-mAbs Therapeutics Announces Resignation Of Chief Financial Officer, Bo Kruse, Will Remain In The Role Until His Successor Is Identified And Joins The Company
YMAB
14 Mar 24
Michael Rossi, President and Chief Executive Officer. "He has been a valued member of our leadership team. Through his responsible capital management
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
YMAB
6 Mar 24
', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Y-mAbs Therapeutics. This offers insight into analysts
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
YMAB
4 Mar 24
in the field of immunotherapy. At Nektar, Dr. Tagliaferri has been responsible for numerous clinical studies evaluating novel therapeutics in oncology and she
- Prev
- 1
- Next